Epigenomics AG

EANS-News: Epigenomics AG
Epigenomics AG to host Press Conference and Analyst Meeting for 2008 Annual Results

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.

companies/press conference

Berlin, Germany and Seattle, WA, U.S.A (euro adhoc) - March 11, 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company will hold its annual press conference and analyst meeting on Tuesday, March 31, 2009 and present results for the fiscal year 2008. Geert Nygaard, CEO and Oliver Schacht, CFO will give an overview of the operational developments as well as provide guidance for 2009. A conference call with Epigenomics' management will be held later on the same day.

Press Conference and Analyst Meeting

The press conference and analyst meeting will be conducted in German and will be held on Tuesday, March 31, 2009 at 10 am to 12 noon CET at the premises of the Villa Bonn - Frankfurter Gesellschaft für Handel Industrie und Wirtschaft in Frankfurt am Main:

Villa Bonn Frankfurter Gesellschaft für Handel Industrie und Wirtschaft Siesmayerstrasse 12 60323 Frankfurt am Main

Room: Vortragsraum (OG)

Epigenomics asks interested parties to confirm their participation for the press conference and analyst meeting by Thursday, March 26, 2009 by fax +49 (0)30 24 34 5- 555 or email ir@epigenomics.com.

Conference Call

A conference call will be held on Tuesday, March 31, 2009 at 3 pm to 4 pm CET (9 am to 10 am EST), hosted by Epigenomics' management to discuss 2008 financial results and outlook for 2009. The conference call will be conducted in English.

Dial-in number (within Germany.): +49 868 71 790

Dial-in number (outside Germany): +1 212 444 0297

Please dial-in at least 10 minutes prior to commencement of the conference call.

To follow the presentation, Epigenomics kindly ask all participants of the call to download the slide set from the company website prior to the call where it will be made available as a PDF file at 10 am CET (4 am EST) on the same day.

Internet link: http://www.epigenomics.com/en/down_loads/corporate_material/

The conference call will be recorded and also made available on the company website web as a MP3 file after the call.

Internet link: http://www.epigenomics.com/en/down_loads/corporate_material/

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests in development aim at diagnosing cancer at an early stage before symptoms occur and thereby may reduce mortality from this dreaded disease.

Epigenomics' product pipeline contains a validated biomarker for the early detection of colorectal cancer in blood plasma, and further proprietary DNA methylation biomarkers at various stages of development for prostate and lung cancer detection in urine, blood and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the early detection of colorectal cancer in a simple blood sample demonstrated continuously highest performance in multiple clinical studies with in total about 3,500 individuals tested.

For development and global commercialization of in vitro diagnostic test products, Epigenomics pursues a non-exclusive partnering strategy. Strategic diagnostics industry partners include Abbott Molecular, Philips, Sysmex Corporation and Quest Diagnostics Incorporated for diagnostics test products and services, and QIAGEN N.V. for sample preparation solutions and research products.

Partners in the health care industry and the biomedical research community can access Epigenomics' portfolio of proprietary DNA methylation technologies and biomarkers protected by more than 150 patent families through research products, Biomarker Services, IVD Development Collaborations, and Licensing. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary in Seattle, WA, U.S.A. For more information, please visit Epigenomics' website at www.epigenomics.com.


Epigenomics' legal disclaimer.

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368

Branche: Biotechnology
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade

Original-Content von: Epigenomics AG, übermittelt durch news aktuell

Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: